Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of BioScrip, Inc.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of shareholders of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS). The investigation focuses on certain statements issued by the Company concerning BioScrip’s business and operations.

BioScrip provides home infusion, other home care services, and pharmacy benefit management services in the United States. The investigation is related to the Company’s September 23, 2013, disclosure that the United States Attorney’s Office for the Southern District of New York and the New York State Attorney General’s Medicaid Fraud Control Unit have undertaken an investigation regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade^(R) by the Company’s legacy specialty pharmacy division. The Company further disclosed that it has provided documents and information to the government regarding the distribution of Exjade, pursuant to a civil investigative demand and a subpoena. Following this news, the price of BioScrip shares declined more than 18%, to a closing price of $8.47 per share on September 24, 2013.

If you purchased BioScrip shares and still hold those shares, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], Toll Free at [phone], or by email to [e-mail], or visit our website at http://www.howardsmithlaw.com.